Lydia Shotton is an accomplished professional with extensive experience in EU Government Affairs within the healthcare and life sciences sector. Currently serving as the Associate Director at the Alliance for Regenerative Medicine, Lydia plays a pivotal role in shaping policy and advocacy strategies to advance the ATMP sector. With a strong background in EU policy and a deep understanding of the complexities of the healthcare landscape, Lydia is dedicated to driving innovation and access to life-changing therapies for patients with rare diseases.
-Why ATMPs are a unique opportunity to modernize HTA and drive the EUs competitiveness
-How do we get there?
-What are the gaps and how to fill them?